Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Research Report 2023

Publication ID:

PB502231011

Publication Date:

February 27, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global High Performance Active Pharmaceutical Ingredients (HPAPI) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for High Performance Active Pharmaceutical Ingredients (HPAPI) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for High Performance Active Pharmaceutical Ingredients (HPAPI) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of High Performance Active Pharmaceutical Ingredients (HPAPI) include Bristol-Myers Squibb, Novartis, Sanofi Aventis, Pfizer, Lonza, Novasep, Hospira, BASF and Merck, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for High Performance Active Pharmaceutical Ingredients (HPAPI), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding High Performance Active Pharmaceutical Ingredients (HPAPI).
The High Performance Active Pharmaceutical Ingredients (HPAPI) market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global High Performance Active Pharmaceutical Ingredients (HPAPI) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the High Performance Active Pharmaceutical Ingredients (HPAPI) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Bristol-Myers Squibb
Novartis
Sanofi Aventis
Pfizer
Lonza
Novasep
Hospira
BASF
Merck
Bayer
Teva Pharmaceuticals
Boehringer Ingelheim
Segment by Type
Synthetic Ingredients
Biological Ingredients
Segment by Application
Oncology
Glaucoma
Anti-diabetic
Cardiovascular
Musculoskeletal
Hormonal
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of High Performance Active Pharmaceutical Ingredients (HPAPI) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of High Performance Active Pharmaceutical Ingredients (HPAPI) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Overview
1.1 Product Overview and Scope of High Performance Active Pharmaceutical Ingredients (HPAPI)
1.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Type
1.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Value Comparison by Type (2023-2029)
1.2.2 Synthetic Ingredients
1.2.3 Biological Ingredients
1.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Segment by Application
1.3.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Value by Application: (2023-2029)
1.3.2 Oncology
1.3.3 Glaucoma
1.3.4 Anti-diabetic
1.3.5 Cardiovascular
1.3.6 Musculoskeletal
1.3.7 Hormonal
1.3.8 Others
1.4 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Estimates and Forecasts
1.4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue 2018-2029
1.4.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales 2018-2029
1.4.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Competition by Manufacturers
2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Manufacturers (2018-2023)
2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Average Price by Manufacturers (2018-2023)
2.4 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of High Performance Active Pharmaceutical Ingredients (HPAPI), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of High Performance Active Pharmaceutical Ingredients (HPAPI), Product Type & Application
2.7 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Competitive Situation and Trends
2.7.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest High Performance Active Pharmaceutical Ingredients (HPAPI) Players Market Share by Revenue
2.7.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 High Performance Active Pharmaceutical Ingredients (HPAPI) Retrospective Market Scenario by Region
3.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Region: 2018-2029
3.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Region: 2018-2023
3.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Region: 2024-2029
3.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Region: 2018-2029
3.3.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Region: 2018-2023
3.3.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Region: 2024-2029
3.4 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Country
3.4.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2018-2029)
3.4.3 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Country
3.5.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2018-2029)
3.5.3 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Country
3.6.1 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2018-2029)
3.6.3 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Country
3.7.1 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2018-2029)
3.7.3 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Country
3.8.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2018-2029)
3.8.3 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2018-2029)
4.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2018-2023)
4.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2024-2029)
4.1.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2018-2029)
4.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Type (2018-2029)
4.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Type (2018-2023)
4.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Type (2024-2029)
4.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Type (2018-2029)
4.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Type (2018-2029)
5 Segment by Application
5.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2018-2029)
5.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2018-2023)
5.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2024-2029)
5.1.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2018-2029)
5.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Application (2018-2029)
5.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Application (2018-2023)
5.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Application (2024-2029)
5.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Application (2018-2029)
5.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Sanofi Aventis
6.3.1 Sanofi Aventis Corporation Information
6.3.2 Sanofi Aventis Description and Business Overview
6.3.3 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.3.5 Sanofi Aventis Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Lonza
6.5.1 Lonza Corporation Information
6.5.2 Lonza Description and Business Overview
6.5.3 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.5.5 Lonza Recent Developments/Updates
6.6 Novasep
6.6.1 Novasep Corporation Information
6.6.2 Novasep Description and Business Overview
6.6.3 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.6.5 Novasep Recent Developments/Updates
6.7 Hospira
6.6.1 Hospira Corporation Information
6.6.2 Hospira Description and Business Overview
6.6.3 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.7.5 Hospira Recent Developments/Updates
6.8 BASF
6.8.1 BASF Corporation Information
6.8.2 BASF Description and Business Overview
6.8.3 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.8.5 BASF Recent Developments/Updates
6.9 Merck
6.9.1 Merck Corporation Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 Bayer
6.10.1 Bayer Corporation Information
6.10.2 Bayer Description and Business Overview
6.10.3 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.10.5 Bayer Recent Developments/Updates
6.11 Teva Pharmaceuticals
6.11.1 Teva Pharmaceuticals Corporation Information
6.11.2 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Description and Business Overview
6.11.3 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.11.5 Teva Pharmaceuticals Recent Developments/Updates
6.12 Boehringer Ingelheim
6.12.1 Boehringer Ingelheim Corporation Information
6.12.2 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Description and Business Overview
6.12.3 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Product Portfolio
6.12.5 Boehringer Ingelheim Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Chain Analysis
7.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Production Mode & Process
7.4 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Marketing
7.4.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Channels
7.4.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Distributors
7.5 High Performance Active Pharmaceutical Ingredients (HPAPI) Customers
8 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Dynamics
8.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Industry Trends
8.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Drivers
8.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Challenges
8.4 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Bristol-Myers Squibb
Novartis
Sanofi Aventis
Pfizer
Lonza
Novasep
Hospira
BASF
Merck
Bayer
Teva Pharmaceuticals
Boehringer Ingelheim

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂